Industry & Policy News

[Mid North Coast Local Health District] Mid North Coast Cancer Institute (MNCCI) announced that Shearwater Lodge has provided a $150,000 grant. Prostate cancer patients at MNCCI will be the first in regional New South Wales to have access to a new type of treatment that dramatically reduces treatment time and waiting lists.

[Immatics N.V.] Immatics N.V. announced that Bristol Myers Squibb has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy candidate from their ongoing collaboration.

[University of Melbourne] The international registry of colorectal cancer patients and relatives, supporting earlier diagnosis and research to improve patient outcomes, has received $8.7 million USD from the US National Institutes of Health.

[Roche] Tapping into exciting new advances in biology, medical and scientific knowledge, technology and data science, the Institue of Human Biology is a cross-disciplinary endeavor bringing together academia and industry. It is focused on creating reliable predictive models that better emulate the human body — and deploying them directly in drug discovery and development.

[NHS Grampian] NHS Grampian’s breast cancer research team is to receive the National Institute for Health Research’s CREST Award. The accolade recognises the surgical team that have made the greatest contribution to clinical trials research across the UK during the last year.

[Cellenkos^®, Inc. (PRNewsire)] Cellenkos® Inc. announced that it has dosed the first patient in a Phase I/Ib study evaluating CK0803 for treatment of amyotrophic lateral sclerosis. CK0803 is a neurotrophic, allogeneic, umbilical cord blood-derived T regulatory cell therapy that preferentially homes towards central nervous system.